582 related articles for article (PubMed ID: 26907620)
1. Stronger Uricosuric Effects of the Novel Selective URAT1 Inhibitor UR-1102 Lowered Plasma Urate in Tufted Capuchin Monkeys to a Greater Extent than Benzbromarone.
Ahn SO; Ohtomo S; Kiyokawa J; Nakagawa T; Yamane M; Lee KJ; Kim KH; Kim BH; Tanaka J; Kawabe Y; Horiba N
J Pharmacol Exp Ther; 2016 Apr; 357(1):157-66. PubMed ID: 26907620
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological Evaluation of Dotinurad, a Selective Urate Reabsorption Inhibitor.
Taniguchi T; Ashizawa N; Matsumoto K; Saito R; Motoki K; Sakai M; Chikamatsu N; Hagihara C; Hashiba M; Iwanaga T
J Pharmacol Exp Ther; 2019 Oct; 371(1):162-170. PubMed ID: 31371478
[TBL] [Abstract][Full Text] [Related]
3. Discovery and characterization of verinurad, a potent and specific inhibitor of URAT1 for the treatment of hyperuricemia and gout.
Tan PK; Liu S; Gunic E; Miner JN
Sci Rep; 2017 Apr; 7(1):665. PubMed ID: 28386072
[TBL] [Abstract][Full Text] [Related]
4. [Uricosuric agent].
Ohno I
Nihon Rinsho; 2008 Apr; 66(4):743-7. PubMed ID: 18409525
[TBL] [Abstract][Full Text] [Related]
5. Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney.
Miner JN; Tan PK; Hyndman D; Liu S; Iverson C; Nanavati P; Hagerty DT; Manhard K; Shen Z; Girardet JL; Yeh LT; Terkeltaub R; Quart B
Arthritis Res Ther; 2016 Oct; 18(1):214. PubMed ID: 27716403
[TBL] [Abstract][Full Text] [Related]
6. Effect of losartan and benzbromarone on the level of human urate transporter 1 mRNA.
Nindita Y; Hamada T; Bahrudin U; Hosoyamada M; Ichida K; Iwai C; Urashima S; Kuwabara M; Utami SB; Mizuta E; Yamada K; Igawa O; Shigemasa C; Ninomiya H; Tsuchihashi T; Hisatome I
Arzneimittelforschung; 2010; 60(4):186-8. PubMed ID: 20486468
[TBL] [Abstract][Full Text] [Related]
7. Interactions of urate transporter URAT1 in human kidney with uricosuric drugs.
Shin HJ; Takeda M; Enomoto A; Fujimura M; Miyazaki H; Anzai N; Endou H
Nephrology (Carlton); 2011 Feb; 16(2):156-62. PubMed ID: 21272127
[TBL] [Abstract][Full Text] [Related]
8. Uricosuric action of losartan via the inhibition of urate transporter 1 (URAT 1) in hypertensive patients.
Hamada T; Ichida K; Hosoyamada M; Mizuta E; Yanagihara K; Sonoyama K; Sugihara S; Igawa O; Hosoya T; Ohtahara A; Shigamasa C; Yamamoto Y; Ninomiya H; Hisatome I
Am J Hypertens; 2008 Oct; 21(10):1157-62. PubMed ID: 18670416
[TBL] [Abstract][Full Text] [Related]
9. [Molecular mechanism in biological transport in the kidney: Urate transporter URAT1].
Hosoyamada M; Shibasaki T; Ichida K
Nihon Rinsho; 2006 Feb; 64 Suppl 2():176-9. PubMed ID: 16523883
[No Abstract] [Full Text] [Related]
10. Uricosuric Agents Affect Plasma and Kidney Concentration of Adefovir via Inhibition of Oat1 and Mrp2 in Rats.
Motoki K; Taniguchi T; Ashizawa N; Sakai M; Chikamatsu N; Yamano K; Iwanaga T
Biol Pharm Bull; 2023; 46(2):170-176. PubMed ID: 36724945
[TBL] [Abstract][Full Text] [Related]
11. Systematic Structure-Activity Relationship (SAR) Exploration of Diarylmethane Backbone and Discovery of A Highly Potent Novel Uric Acid Transporter 1 (URAT1) Inhibitor.
Cai W; Wu J; Liu W; Xie Y; Liu Y; Zhang S; Xu W; Tang L; Wang J; Zhao G
Molecules; 2018 Jan; 23(2):. PubMed ID: 29382075
[TBL] [Abstract][Full Text] [Related]
12. Involvement of uric acid transporter in increased renal clearance of the xanthine oxidase inhibitor oxypurinol induced by a uricosuric agent, benzbromarone.
Iwanaga T; Kobayashi D; Hirayama M; Maeda T; Tamai I
Drug Metab Dispos; 2005 Dec; 33(12):1791-5. PubMed ID: 16135657
[TBL] [Abstract][Full Text] [Related]
13. Functional cooperation of URAT1 (SLC22A12) and URATv1 (SLC2A9) in renal reabsorption of urate.
Nakanishi T; Ohya K; Shimada S; Anzai N; Tamai I
Nephrol Dial Transplant; 2013 Mar; 28(3):603-11. PubMed ID: 23291366
[TBL] [Abstract][Full Text] [Related]
14. Morin (3,5,7,2',4'-pentahydroxyflavone) exhibits potent inhibitory actions on urate transport by the human urate anion transporter (hURAT1) expressed in human embryonic kidney cells.
Yu Z; Fong WP; Cheng CH
Drug Metab Dispos; 2007 Jun; 35(6):981-6. PubMed ID: 17325024
[TBL] [Abstract][Full Text] [Related]
15. Synthesis of novel benzbromarone derivatives designed to avoid metabolic activation.
Ohe T; Umezawa R; Kitagawara Y; Yasuda D; Takahashi K; Nakamura S; Abe A; Sekine S; Ito K; Okunushi K; Morio H; Furihata T; Anzai N; Mashino T
Bioorg Med Chem Lett; 2018 Dec; 28(23-24):3708-3711. PubMed ID: 30389287
[TBL] [Abstract][Full Text] [Related]
16. Urate Transporter URAT1 in Hyperuricemia: New Insights from Hyperuricemic Models.
Li X; Yan Z; Tian J; Zhang X; Han H; Ye F
Ann Clin Lab Sci; 2019 Nov; 49(6):756-762. PubMed ID: 31882426
[TBL] [Abstract][Full Text] [Related]
17. (E)-2-(4-bromophenyl)-1-(2, 4-dihydroxyphenyl)ethanone oxime is a potential therapeutic agent for treatment of hyperuricemia through its dual inhibitory effects on XOD and URAT1.
Hu Q; Zhou M; Zhu H; Lu G; Zheng D; Li H; Hao K
Biomed Pharmacother; 2017 Feb; 86():88-94. PubMed ID: 27951420
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, and biological studies of dual URAT1 inhibitor and FXR agonist based on benzbromarone.
Huang W; Jiao S; Chen S; Chen Y; Yang Z; Wang W; Cao Z; Li Z; Zhang L
Bioorg Med Chem; 2022 Dec; 75():117073. PubMed ID: 36347120
[TBL] [Abstract][Full Text] [Related]
19. Omega-3 Polyunsaturated Fatty Acids Inhibit the Function of Human URAT1, a Renal Urate Re-Absorber.
Saito H; Toyoda Y; Takada T; Hirata H; Ota-Kontani A; Miyata H; Kobayashi N; Tsuchiya Y; Suzuki H
Nutrients; 2020 May; 12(6):. PubMed ID: 32486008
[TBL] [Abstract][Full Text] [Related]
20. Novel urate transporter 1 (URAT1) inhibitors: a review of recent patent literature (2016-2019).
Dong Y; Zhao T; Ai W; Zalloum WA; Kang D; Wu T; Liu X; Zhan P
Expert Opin Ther Pat; 2019 Nov; 29(11):871-879. PubMed ID: 31593642
[No Abstract] [Full Text] [Related]
[Next] [New Search]
